Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2014 Earnings Results

Alnylam Pharmaceuticals Misses on EPS, Stock Down 2.04%

Alnylam Pharmaceuticals reported a loss that was worse than expected, leading to a 2.04% decline in stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's short-term outlook. Management's cautious tone suggests they are aware of challenges ahead but are committed to long-term strategies.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.63	N/A	-16.67%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concerns about current market conditions. They highlighted a commitment to navigating challenges while focusing on long-term goals.

Management acknowledged the challenges faced during the quarter.

They emphasized ongoing efforts to improve operational efficiency.

Future strategies were discussed, but specifics were limited.

Alnylam Pharmaceuticals Misses on EPS, Stock Down 2.04%

Key numbers

Management commentary

Alnylam Pharmaceuticals, Inc.

More earnings this week

Alnylam Pharmaceuticals Misses on EPS, Stock Down 2.04%

Key numbers

Management commentary